362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis
oleh: Emmett Schmidt, Jonathan Thompson, Michael Chisamore, James Spicer, Åslaug Helland, Edurne Arriola, Manuel Dómine Gomez, Jose Manuel Trigo Perez, Ana Laura Ortega Granados, Noelly Madeleine, Austin Rayford, Katherine Lorens, Abdul Siddiqui, Hani Gabra, Jaya Nautiyal, David Micklem, James Lorens
| Format: | Article |
|---|---|
| Diterbitkan: | BMJ Publishing Group 2020-11-01 |
Deskripsi
No description available for this item.